BACKGROUND: In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+). We conducted annual surveys from 2008 to 2012 to determine the effect of PCV13 on colonization by pneumococcal serotypes. METHODS: We obtained nasopharyngeal swabs for pneumococcal identification and serotyping from residents of all ages at 8 rural villages and children age <60 months at 2 urban clinics. We conducted interviews/medical records review for all participants. RESULTS: A total of 18 207 nasopharyngeal swabs (rural = 16 098; urban = 2109) were collected. From 2008 to 2012, 84% of rural and 90% of urban children age <5 years were age-appropriately vaccinated with a PCV. Overall pneumococcal colonization prevalence remained stable among rural (66%) and urban (35%) children age <5 years, and adults age ≥18 years (14%). Colonization by PCV6+ serotypes declined significantly among rural children age <5 years, urban children age <5, and adults age ≥18 over the course of the study (25%-5%, 22%-9%, 22%-6%, respectively). CONCLUSIONS: PCV13 was rapidly introduced into the Alaska childhood immunization schedule and reduced colonization by PCV6+ serotypes among children. Unvaccinated adults also experienced comparable reductions in vaccine serotype colonization indicating substantial indirect protection from PCV13.
BACKGROUND: In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+). We conducted annual surveys from 2008 to 2012 to determine the effect of PCV13 on colonization by pneumococcal serotypes. METHODS: We obtained nasopharyngeal swabs for pneumococcal identification and serotyping from residents of all ages at 8 rural villages and children age <60 months at 2 urban clinics. We conducted interviews/medical records review for all participants. RESULTS: A total of 18 207 nasopharyngeal swabs (rural = 16 098; urban = 2109) were collected. From 2008 to 2012, 84% of rural and 90% of urban children age <5 years were age-appropriately vaccinated with a PCV. Overall pneumococcal colonization prevalence remained stable among rural (66%) and urban (35%) children age <5 years, and adults age ≥18 years (14%). Colonization by PCV6+ serotypes declined significantly among rural children age <5 years, urban children age <5, and adults age ≥18 over the course of the study (25%-5%, 22%-9%, 22%-6%, respectively). CONCLUSIONS: PCV13 was rapidly introduced into the Alaska childhood immunization schedule and reduced colonization by PCV6+ serotypes among children. Unvaccinated adults also experienced comparable reductions in vaccine serotype colonization indicating substantial indirect protection from PCV13.
Authors: M Davidson; C D Schraer; A J Parkinson; J F Campbell; R R Facklam; R B Wainwright; A P Lanier; W L Heyward Journal: JAMA Date: 1989-02-03 Impact factor: 56.272
Authors: W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin Journal: Bull World Health Organ Date: 1985 Impact factor: 9.408
Authors: Matthew R Moore; Terri B Hyde; Thomas W Hennessy; Debra J Parks; Alisa L Reasonover; Marcella Harker-Jones; James Gove; Dana L Bruden; Karen Rudolph; Alan Parkinson; Jay C Butler; Anne Schuchat Journal: J Infect Dis Date: 2004-10-27 Impact factor: 5.226
Authors: Thomas W Hennessy; Troy Ritter; Robert C Holman; Dana L Bruden; Krista L Yorita; Lisa Bulkow; James E Cheek; Rosalyn J Singleton; Jeff Smith Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney Journal: J Infect Dis Date: 2007-10-04 Impact factor: 5.226
Authors: Prabhu P Gounder; Robert C Holman; Sara M Seeman; Alice J Rarig; Mary McEwen; Claudia A Steiner; Michael L Bartholomew; Thomas W Hennessy Journal: Public Health Rep Date: 2016-12-12 Impact factor: 2.792
Authors: Lindsay R Grant; Laura L Hammitt; Sarah E O'Brien; Michael R Jacobs; Connie Donaldson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien Journal: Pediatr Infect Dis J Date: 2016-08 Impact factor: 2.129
Authors: Miwako Kobayashi; Lara Misegades; Katherine E Fleming-Dutra; Sana Ahmed; Ryan Gierke; Srinivas Nanduri; Jessica M Healy; Duong T Nguyen; Maria da Gloria Carvalho; Fabiana Pimenta; Stephen H Waterman; Matthew R Moore; Curi Kim; Cynthia G Whitney Journal: Pediatr Infect Dis J Date: 2017-02 Impact factor: 2.129
Authors: Michelle McFarland; Taylor P Szasz; Julie Y Zhou; Kara Motley; Janardan S Sivapalan; Megan Isaacson-Schmid; Elizabeth M Todd; Patrick G Hogan; Stephanie A Fritz; Carey-Ann D Burnham; Steen Hoffmann; Sharon Celeste Morley Journal: Vaccine Date: 2017-07-04 Impact factor: 3.641
Authors: Prabhu P Gounder; Melissa Brewster; Michael G Bruce; Dana J T Bruden; Karen Rudolph; Debby A Hurlburt; Thomas W Hennessy Journal: Pediatr Infect Dis J Date: 2015-11 Impact factor: 2.129